A highly stimulating programme on pharmaceutical R&D and BD&L in the form of a boardgame called Risky Business.
Read more…
Courses for R&D portfolio managers and R&D project leaders and teams to improve strategic decision making.
Read more…
Customised ProgammesWe tailor existing courses on strategy and decision analysis or create new courses for specific training needs.
Read more…
The Academy was originally set up to support implementation of consulting projects at clients of Catenion. Today, its services are offered to all−comers.
While Catenion provides management consulting services by addressing concrete client issues, the Academy teaches client personnel how to use the analytical tools and methods developed and validated in Catenion“s consulting business.
Dr. Matthias Krings
Partner
Munich and Berlin, Germany
Phone Germany: +49 163 850 91 54
Email: matthias.krings@catenion.com
Matthias is a founding Partner of Catenion who lives in Munich and Berlin, Germany. Matthias became a consultant in 1999 at Mercer Management Consulting and later joined a strategy consulting boutique, Theron. In 2003, he co−founded Catenion.
Matthias has worked for European and global client organisations on pharmaceutical strategy with a particular focus on R&D portfolio management. He has co−developed and applied specialised approaches and tools to assess and mitigate the technical and scientific risks of pharmaceutical R&D projects, as well as link these methods and tools to portfolio−level decision−making. Matthias continuously helps clients master Catenion's consulting approaches and embed them into management routines.
In 2007, Matthias spearheaded the launch of the executive training and education unit of Catenion, The Catenion Academy, with the goal of significantly improving the way clients manage R&D.
Before commencing his studies, Matthias lived and worked in Florida for a year. He holds a diploma and a doctorate degree in biology from the Ludwig−Maximilians University in Munich. His PhD work was supported by a scholarship from the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine. During his academic period, Matthias made significant scientific contributions to the field of human evolution. Matthias' and his research team's analysis of the first−ever DNA sequence from the Neanderthal−type specimen in 1997 continues to be one of the most frequently cited papers in the field of evolution. This and subsequent studies showed that Neanderthal mitochondrial DNA falls outside the variation of contemporary modern humans, suggesting that little or no interbreeding may have taken place between the two.
In private, Matthias likes to be with family and friends. He enjoys a variety of music, gardening, cooking, and water sports and is interested in human evolution and evolutionary psychology.